Disclaimer: Views expressed are solely those of Douglas Clark, and do not represent the opinions or positions of the Patented Medicine Prices Review Board or the Government of Canada.
On March 6, 2014 the keynote address of the conference was delivered by Mr. Douglas Clark, Executive Director of the Patented Medicine Prices Review Board (PMPRB).
Mr. Clark discussed the role of the PMPRB, how it sets prices for patented medicines, and its limited jurisdiction. He explained that the PMPRB determines prices for patented medicines based on their innovativeness and through consideration of prices set by specific reference countries.
Mr. Clark also identified what he considered to be some relevant challenges under the current system. These include the tendency toward non-transparent pricing agreements, the decrease in medicine prices in Canada’s price comparator countries, and the impact of new trade agreements (eg. Comprehensive Economic and Trade Agreement).
At the end of the presentation, audience members were invited to think about how therapeutic value of medicines ought to be defined and how best to achieve sustainable pricing policies for payers.